Clinical trials: Patient Non-Compliance
Bipolar Disorder, Schizophrenia
Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study
Feasibility study of using a digital health feedback system (DHFS) to monitor medication-taking and physiologic and behavioral parameters in patients with bipolar disorder or schizophrenia.
- Trial name
- EMITTER3PSY (NCT01804257)
- Testing
- Digital Health Feedback System
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Proteus Digital Health, Inc.
Patient Satisfaction
Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment
The main aim of the study is to investigate patient satisfaction in the treatment of asthma and COPD with the new device of DuoResp® Spiromax® and patient preference.
- Trial name
- NCT02384577
- Testing
- Budesonide, Formoterol Fumarate Dihydrate
- Where
- Germany
- Volunteers
- 4,034 people
- Sponsor
- Teva Pharma GmbH
Chronic Lymphocytic Leukemia
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Since in most cases CLL remains an incurable disease, the goals of therapy are to improve quality of life and to prolong survival.
- Trial name
- PROVIDENCE (NCT06125795)
- Where
- 25 sites in Spain
- Volunteers
- 146 people
- Sponsor
- AbbVie
Multiple Sclerosis, Relapsing-Remitting
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data.
- Trial name
- NCT06897657
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer
The objectives of this study is to obtain information of Faslodex use in the treatment of breast cancer in the clinical practice in Argentina.
- Trial name
- FRAME (NCT00878930)
- Where
- 16 sites in Argentina
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Stroke
Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.
AiCure uses artificial intelligence and visual recognition technology to confirm medication ingestion. The software is available as an app and downloaded onto a smart phone.
- Trial name
- NCT02599259
- Testing
- Monitored (M+)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- AiCure
Gastrointestinal Hemorrhage, Ulcer
Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer
The purpose of this study is to assess gastroprotective agent compliance in patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer with NSAID.
- Trial name
- NCT01215058
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Opiate Addiction, Medication Non-adherence
Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy
This study uses an artificial intelligence platform to automatically confirm medication ingestion. The Health Insurance Portability and Accountability Act (HIPAA)-compliant platform can be downloaded as an 'app' onto any…
- Conditions
- Opiate Addiction, Medication Non-adherence, Addiction, Opioid Dependence
- Trial name
- NCT02243670
- Testing
- AiCure monitoring and intervention
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- AiCure
Hypertension, Non-Adherence, Patient
Telehealth Intervention for Improved Blood Pressure Control With Targeted Incentives
Hypertension is the leading risk factor for cardiovascular disease, global mortality, and ranks third among the causes of disability.
- Trial name
- NCT04075045
- Testing
- Wellth Smartphone App, Targeted Incentives, Non-Restricted Incentives
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Wellth Inc.
Hepatitis C, Chronic, Hepatitis C
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not.
- Trial name
- NCT00728494
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908), Patient Assistance Program
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Neoplasms, Prostatic Neoplasms
Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
Adherence (or compliance with) a medication regimen is generally defined as the extent to which patients take medication as prescribed by their health care providers.
- Conditions
- Breast Neoplasms, Prostatic Neoplasms, Multiple Myeloma, Osteolysis
- Trial name
- BONA (NCT01198457)
- Testing
- Clodronate (Bonefos, BAY94-8393)
- Where
- Czechia
- Volunteers
- 147 people
- Sponsor
- Bayer
Hyperlipidemia
Compliance With Treatment For Patients With Hyperlipidemia
It is a prospective observational study. Patients will be high risk patients (for developing cardiovascular events) that are treated with a statin.
- Trial name
- COLL (NCT00828945)
- Testing
- Lipid Self Test
- Where
- 17 sites in Sweden
- Volunteers
- 259 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Breast Neoplasms
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
This non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer…
- Trial name
- CAROLEEN (NCT06830720)
- Testing
- ribociclib + AI ± LHRH, abemaciclib + ET ± LHRH, ET mono ± LHRH
- Where
- 287 sites in Austria, Germany
- Volunteers
- 3,250 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus
To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.
- Trial name
- COMBAT (NCT00526279)
- Where
- 3 sites in South Korea
- Volunteers
- 9,000 people
- Sponsor
- AstraZeneca
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
Low Back Pain
Lumbar Belt Benefit Compared to the Usual Care in the Treatment of Non-specific Low Back Pain
Lumbar belt benefit compared to the usual care in the treatment of non-specific low back pain -an interventional, prospective, multicenter, randomized, open and controlled.study
- Trial name
- LOMBACT (NCT04701073)
- Testing
- LombaStab belt
- Where
- 3 sites in France
- Volunteers
- 168 people
- Sponsor
- Thuasne
Colorectal Cancer
Adherence to Minimally Invasive Testing
Colorectal cancer (CRC) screening has been demonstrated to reduce long term disease burden and costs. Unfortunately, less than 65 % of age-eligible persons in the US are actually screened for CRC.
- Trial name
- ADMIT (NCT02251782)
- Testing
- Epi proColon Test, Fecal Immunochemical Test (FIT)
- Where
- 2 sites in United States
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc
Multiple Myeloma, Newly Diagnosed
Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
MYLENE is a prospective, multicenter, NIS to evaluate the patient and HCP satisfaction of sc and iv application of daratumumab in routine clinical practice in Germany.
- Conditions
- Multiple Myeloma, Newly Diagnosed, Transplant Ineligible, Patient Satisfaction
- Trial name
- MYLENE (NCT05284591)
- Testing
- Daratumumab
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- iOMEDICO AG
Contraception
Data on Oral Contraceptives Compliance in Non Stop Regimen
Adherence to the dosing scheme is the principal element of COC efficiency. On the other hand noncompliance seemed to be an inseparable element of any oral treatment.
- Trial name
- DOC Non Stop (NCT01185678)
- Testing
- Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)
- Where
- Poland
- Volunteers
- 8,416 people
- Sponsor
- Bayer
Epilepsy
IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.
This is a retrospective non-interventional study to describe the HCRU and clinical outcomes before and after AspireSR® device implantation in subjects with drug resistant epilepsy at the Queen Elizabeth Hospital, Birmingham…
- Trial name
- IMPACT (NCT05975931)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- LivaNova